Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ario Pharma Founded to Develop Novel Therapeutics for Respiratory Indications

Published: Thursday, December 12, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
Developing best in class TRPV1 antagonist for treatment of cough.

Ario Pharma Ltd has been founded to develop innovative new approaches to treat respiratory disease. Based in Cambridge, UK, Ario Pharma is a spin out from Xention Pharma Ltd, a specialist ion channel R&D company.

Ario Pharma has announced that it has successfully raised £1.9 million ($3.1 million) from an international syndicate of New Science Ventures, Forbion Capital Partners and Seroba Kernel Life Sciences.

The funding will be used to execute two separate Phase 2 trials for the Company’s lead product, XEN-D0501, in chronic idiopathic cough and cough associated with chronic obstructive pulmonary disease (COPD). XEN-D0501 is a potential best in class, orally bioavailable inhibitor of TRPV1.

Ario Pharma expects to commence the Phase 2 trials in Q1 2014. XEN-D0501 has successfully completed multiple Phase 1 studies and has been shown to be safe and well tolerated.

The Phase 2 trials will be randomized, double-blind, placebo-controlled cross-over studies and will use validated ambulatory cough monitoring technology developed by Dr. Jacky Smith from the University Hospital of South Manchester.

The Company’s Scientific Advisory Board is comprised of world-renowned UK experts in respiratory disease including Professor Maria Belvisi and Dr Mark Birrell from the National Heart and Lung Institute, Imperial College London and Professor Dave Singh and Dr Jacky Smith from the University of Manchester and University Hospital of South Manchester.

Dr John Ford, CEO of Ario Pharma, commented: “Cough is one of the most common symptoms for which patients seek medical care, and yet current medications are either poorly effective or have serious side effects. There is growing evidence for the involvement of TRP channels in driving cough reflex hypersensitivity and inflammatory responses in diseases associated with cough. We are therefore delighted to have secured investment to fund multiple Phase 2 trials that will evaluate the efficacy of XEN-D0501. We plan to build on the emerging role of TRPV1 in other respiratory diseases and to initiate discovery projects against other TRP channels that play a role in respiratory disease”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ario Pharma Strengthens Scientific Advisory Board
Professor Peter Barnes and Professor Wisia Wedzicha appointed with immediate effect.
Monday, May 12, 2014
Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!